What is MedAware?
MedAware offers an AI-powered medication safety monitoring platform designed to identify preventable medication-related risks throughout the patient journey. The platform integrates seamlessly with existing health data systems and devices, providing a safety layer that enhances patient safety and operational outcomes. Targeting healthcare providers, including hospitals and clinics, MedAware's technology aims to improve decision support and reduce medication errors. With its innovative approach, MedAware is positioned as a critical tool for enhancing medication safety in various care settings.
How much funding has MedAware raised?
MedAware has raised a total of $9.3M across 3 funding rounds:
Grant
$25K
Other Financing Round
$1.3M
Series A
$8M
Grant (2015): $25K with participation from MedTech Innovator companies
Other Financing Round (2016): $1.3M led by OurCrowd and Winton Ventures
Series A (2017): $8M supported by OurCrowd, Gefen Capital, and Becton, Dickinson and Company
Key Investors in MedAware
OurCrowd
OurCrowd is an investment platform that enables accredited investors and institutions to invest in startups and early-stage companies, with a strong presence in Israel.
Gefen Capital
Gefen Capital is a venture capital firm known for its flexible investment strategy and a robust network in the US, focusing on companies with strong technological differentiation and large market potential.
Becton, Dickinson and Company
BD is a global medical technology company that develops and manufactures medical devices, diagnostic systems, and healthcare solutions, supporting hospitals and healthcare providers with innovations in patient safety and drug delivery.
What's next for MedAware?
The substantial enterprise-level backing indicates MedAware is poised for significant scaling and market penetration. Future strategic initiatives will likely focus on expanding the platform's integration capabilities across diverse healthcare IT infrastructures and further developing its AI algorithms to predict and mitigate an even broader spectrum of medication-related risks. Continued investment in research and development, coupled with strategic partnerships, will be crucial for MedAware to solidify its position as a leader in medication safety technology and drive widespread adoption among healthcare providers seeking to improve patient outcomes and operational efficiency.
See full MedAware company page
